title: Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole.
abstract: This magnetoencaphalographic (MEG) study was conducted as part of a multicenter clinical trial to study the efficacy of aripiprazole. Participants included 5 DSM-IV schizophrenia subjects and 10 age-matched normal controls. The schizophrenia subjects underwent a second MEG recording after 8 weeks of open-label treatment with aripiprazole. Overall, control subjects showed no abnormal spontaneous magnetic brain activity. At washout, 3 patients showed increased delta and theta activity along with paraxosymal bitemporal slow waves. In 2 of these patients, the slow waves were generated in the superior temporal plane, as determined by dipole modeling. In the third patient, the slow waves appeared to have been generated at multiple regions throughout the temporal and inferior parietal lobes. As a group, schizophrenia patients, when compared with normal controls, demonstrated significant decreases in alpha peak frequency and power. Following treatment, aripiprazole had a significant normalizing effect on delta and theta activity. Patients on aripiprazole continued to demonstrate significant abnormalities in alpha frequency and power.
authors.affiliation: Department of Psychiatry, New Mexico Regional Federal Medical Center, Albuquerque 87108, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Cañive
authors.forename: J D
authors.initials: JD
authors.lastname: Lewine
authors.forename: J C
authors.initials: JC
authors.lastname: Edgar
authors.forename: J T
authors.initials: JT
authors.lastname: Davis
authors.forename: G A
authors.initials: GA
authors.lastname: Miller
authors.forename: F
authors.initials: F
authors.lastname: Torres
authors.forename: V B
authors.initials: VB
authors.lastname: Tuason
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D004311:Double-Blind Method; D004569:Electroencephalography; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole